fentanyl has been researched along with HbS Disease in 15 studies
Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078)
fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Severe pain is defined as rated seven or greater on a 0 to 10 age-appropriate numeric pain scale or equivalent." | 6.77 | Intranasal fentanyl versus intravenous morphine in the emergency department treatment of severe painful sickle cell crises in children: study protocol for a randomised controlled trial. ( an Fhailí, S; Barrett, MJ; Cronin, J; Grant, T; Hayden, J; McCoy, S; McMahon, C; Murphy, A; O'Sullivan, R; Wakai, A; Walsh, S, 2012) |
| " Four interventions were used: a standardized time-specific VOE protocol; intranasal fentanyl as the first parenteral pain medication; an SCD pain medication calculator; and provider and patient/family education." | 5.20 | Improving the Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department. ( Barry, K; Champigny, M; Dorfman, D; Kavanagh, PL; Killius, K; Miner, R; Moses, JM; Sobota, A; Sprinz, PG; Wolfgang, TL, 2015) |
| "To determine if intranasal fentanyl is equally as effective as IV morphine for treating VOC-associated pain in adult SCD patients." | 4.31 | IF IM in a crisis: Intranasal fentanyl versus intravenous morphine in adult vaso-occlusive crisis. ( Assad, O; Brown, K; Melnitsky, L; Moses, J; Sherman, V; Zamora, R, 2023) |
| "Epidural analgesia with local anesthetics administered alone or in combination with fentanyl effectively and safely treats the pain of sickle cell vaso-occlusive crisis unresponsive to conventional pain management and does so without causing sedation, respiratory depression, or significant limitation on ambulation." | 3.69 | Epidural analgesia in the management of severe vaso-occlusive sickle cell crisis. ( Billett, C; Casella, JF; Dover, G; Tobin, JR; Yaster, M, 1994) |
| "Severe pain is defined as rated seven or greater on a 0 to 10 age-appropriate numeric pain scale or equivalent." | 2.77 | Intranasal fentanyl versus intravenous morphine in the emergency department treatment of severe painful sickle cell crises in children: study protocol for a randomised controlled trial. ( an Fhailí, S; Barrett, MJ; Cronin, J; Grant, T; Hayden, J; McCoy, S; McMahon, C; Murphy, A; O'Sullivan, R; Wakai, A; Walsh, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 1 (6.67) | 29.6817 |
| 2010's | 7 (46.67) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Assad, O | 2 |
| Zamora, R | 2 |
| Brown, K | 2 |
| Melnitsky, L | 2 |
| Moses, J | 2 |
| Sherman, V | 2 |
| Rees, CA | 1 |
| Brousseau, DC | 1 |
| Ahmad, FA | 1 |
| Bennett, J | 1 |
| Bhatt, S | 1 |
| Bogie, A | 1 |
| Brown, KM | 1 |
| Casper, TC | 1 |
| Chapman, LL | 1 |
| Chumpitazi, CE | 1 |
| Cohen, DM | 1 |
| Dampier, C | 1 |
| Ellison, AM | 1 |
| Grasemann, H | 1 |
| Hatabah, D | 1 |
| Hickey, RW | 1 |
| Hsu, LL | 1 |
| Bakshi, N | 1 |
| Leibovich, S | 1 |
| Patil, P | 2 |
| Powell, EC | 1 |
| Richards, R | 1 |
| Sarnaik, S | 1 |
| Weiner, DL | 1 |
| Morris, CR | 2 |
| Oni, MO | 1 |
| Archer, NM | 1 |
| Myrick, R | 1 |
| Blakemore, S | 1 |
| Waite, E | 1 |
| Pernell, B | 1 |
| Madan-Swain, A | 1 |
| Hilliard, L | 1 |
| Lebensburger, J | 1 |
| Carden, MA | 1 |
| Ahmad, ME | 1 |
| Lam, WA | 1 |
| Joiner, CH | 1 |
| Kelly, GS | 1 |
| Stewart, RW | 1 |
| Strouse, JJ | 1 |
| Anders, JF | 1 |
| Belmont, AP | 1 |
| Nossair, F | 1 |
| Brambilla, D | 1 |
| Friedman, M | 1 |
| Boswinkel, J | 1 |
| Bradford, AB | 1 |
| Kwiatkowski, JL | 1 |
| De Franceschi, L | 1 |
| Mura, P | 1 |
| Schweiger, V | 1 |
| Vencato, E | 1 |
| Quaglia, FM | 1 |
| Delmonte, L | 1 |
| Evangelista, M | 1 |
| Polati, E | 1 |
| Olivieri, O | 1 |
| Finco, G | 1 |
| Kavanagh, PL | 1 |
| Sprinz, PG | 1 |
| Wolfgang, TL | 1 |
| Killius, K | 1 |
| Champigny, M | 1 |
| Sobota, A | 1 |
| Dorfman, D | 1 |
| Barry, K | 1 |
| Miner, R | 1 |
| Moses, JM | 1 |
| Fein, DM | 1 |
| Avner, JR | 1 |
| Scharbach, K | 1 |
| Manwani, D | 1 |
| Khine, H | 1 |
| Barrett, MJ | 1 |
| Cronin, J | 1 |
| Murphy, A | 1 |
| McCoy, S | 1 |
| Hayden, J | 1 |
| an Fhailí, S | 1 |
| Grant, T | 1 |
| Wakai, A | 1 |
| McMahon, C | 1 |
| Walsh, S | 1 |
| O'Sullivan, R | 1 |
| Shaiova, L | 1 |
| Wallenstein, D | 1 |
| Yaster, M | 1 |
| Tobin, JR | 1 |
| Billett, C | 1 |
| Casella, JF | 1 |
| Dover, G | 1 |
| Kingsley, CP | 1 |
| Chronister, T | 1 |
| Cohen, DJ | 1 |
| Parrish, JM | 1 |
| Drew, R | 1 |
| Bongiovanni, MB | 1 |
| Christensen, ML | 1 |
| Wang, WC | 1 |
| Harris, S | 1 |
| Eades, SK | 1 |
| Wilimas, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Emergency Department: a Double Blind Randomized Versus Placebo Controlled Trial[NCT06181695] | Phase 3 | 182 participants (Anticipated) | Interventional | 2024-05-02 | Not yet recruiting | ||
| A Randomized Trial of Intranasal Fentanyl Versus Placebo as an Adjunct to Lidocaine Infiltration in Adults Undergoing Abscess Incision and Drainage in the Emergency[NCT03872700] | Phase 3 | 49 participants (Actual) | Interventional | 2019-08-01 | Completed | ||
| Intranasal Fentanyl Versus Intravenous Morphine in the Emergency Department Treatment of Severe Painful Sickle Cell Crises in Children[NCT03682211] | Phase 4 | 31 participants (Actual) | Interventional | 2012-12-12 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patient reported NRS pain scores after Blunt Dissection. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 4.1 |
| Placebo | 4.4 |
Patient reported NRS pain scores after Irrigation. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 3.4 |
| Placebo | 2.6 |
Patient reported NRS pain scores after Lidocaine injection. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Following Lidocaine injection measured once anytime up to 12 minutes after intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 8.4 |
| Placebo | 8.0 |
Patient reported pain after Packing of abscess. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once at the time of completion of application of the bandage, up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 4.5 |
| Placebo | 3.9 |
Patient reported NRS pain scores following Incision. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once anytime up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 3.9 |
| Placebo | 3.9 |
Patient reported pain scores at baseline. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 8.3 |
| Placebo | 8.1 |
Patient reported pain scores for overall Procedure assessed immediately after placement of dressing at the end of procedure. The NRS for pain is a reliable and validated measure of pain intensity ranging from 0 - no pain, to 10 - worst pain imaginable. (NCT03872700)
Timeframe: Measured once following placement of dressing at completion of procedure, up to 60 minutes following intranasal administration
| Intervention | score on a scale (Mean) |
|---|---|
| Intranasal Fentanyl | 6.2 |
| Placebo | 7.0 |
4 trials available for fentanyl and HbS Disease
11 other studies available for fentanyl and HbS Disease
| Article | Year |
|---|---|
IF IM in a crisis: Intranasal fentanyl versus intravenous morphine in adult vaso-occlusive crisis.
Topics: Administration, Intranasal; Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Bradycardia; | 2023 |
IF IM in a crisis: Intranasal fentanyl versus intravenous morphine in adult vaso-occlusive crisis.
Topics: Administration, Intranasal; Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Bradycardia; | 2023 |
IF IM in a crisis: Intranasal fentanyl versus intravenous morphine in adult vaso-occlusive crisis.
Topics: Administration, Intranasal; Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Bradycardia; | 2023 |
IF IM in a crisis: Intranasal fentanyl versus intravenous morphine in adult vaso-occlusive crisis.
Topics: Administration, Intranasal; Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Bradycardia; | 2023 |
Intranasal fentanyl and discharge from the emergency department among children with sickle cell disease and vaso-occlusive pain: A multicenter pediatric emergency medicine perspective.
Topics: Analgesics, Opioid; Anemia, Sickle Cell; Child; Cross-Sectional Studies; Emergency Service, Hospital | 2023 |
Intranasal fentanyl works-Why are we not using it more to treat acute pain in sickle cell disease?
Topics: Acute Pain; Administration, Intranasal; Analgesics, Opioid; Anemia, Sickle Cell; Fentanyl; Humans | 2023 |
Outpatient pain clinic and intranasal fentanyl to improve sickle cell disease outcomes.
Topics: Acute Pain; Administration, Intranasal; Adolescent; Analgesics, Opioid; Anemia, Sickle Cell; Child; | 2020 |
Variations in pediatric emergency medicine physician practices for intravenous fluid management in children with sickle cell disease and vaso-occlusive pain: A single institution experience.
Topics: Administration, Intravenous; Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Child; Chil | 2018 |
Intranasal fentanyl improves time to analgesic delivery in sickle cell pain crises.
Topics: Administration, Intranasal; Adolescent; Analgesics, Opioid; Anemia, Sickle Cell; Female; Fentanyl; H | 2018 |
Safety of deep sedation in young children with sickle cell disease: a retrospective cohort study.
Topics: Acute Chest Syndrome; Adjuvants, Anesthesia; Anemia, Sickle Cell; Child; Child, Preschool; Deep Seda | 2015 |
Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease.
Topics: Administration, Buccal; Adolescent; Adult; Analgesics, Opioid; Anemia, Sickle Cell; Anti-Inflammator | 2016 |
Outpatient management of sickle cell pain with chronic opioid pharmacotherapy.
Topics: Adult; Ambulatory Care; Analgesics, Opioid; Anemia, Sickle Cell; Female; Fentanyl; Humans; Male; Met | 2004 |
Epidural analgesia in the management of severe vaso-occlusive sickle cell crisis.
Topics: Analgesia, Epidural; Anemia, Sickle Cell; Child; Emergencies; Female; Fentanyl; Humans; Lidocaine; M | 1994 |
Case 2--1996. Anesthetic management of a patient with hemoglobin SS disease and mitral insufficiency for mitral valve repair.
Topics: Anemia, Sickle Cell; Anesthesia, Intravenous; Anesthetics, Intravenous; Cardiopulmonary Bypass; Eryt | 1996 |